Ulipristal acetate-d is intended for use as an internal standard for the quantification of ulipristal acetate by GC- or LC-MS. Ulipristal acetate is a selective progesterone receptor modulator (SPRM) that binds to the human progesterone receptors PR-A and PR-B (ECs = 8.5 and 7.7 nM, respectively), rabbit uterine PR (EC = 13.6 nM), and rabbit thymic glucocorticoid receptor (GR; EC = 15.4 nM). It is selective for human progesterone receptors over the human estrogen receptor (ER; EC = >10,000 nM). It inhibits growth of IGROV-1 and SK-OV-3 human ovarian cancer cells (ICs = 15.5 and 31.5 μM, respectively) even after resistance to combined cisplatin and paclitaxel treatment has developed. Ulipristal acetate reverses the proliferative effect of progesterone on patient-derived germline mutant BRCA1 breast tissue xenografts in ovariectomized athymic mice. Ulipristal acetate (40 mg/kg, i.p.) administered to female mice within 6 hours of human chorionic gonadotropin (hCG) treatment inhibits ovulation. Formulations containing ulipristal acetate have been used as emergency contraceptives and to treat uterine fibroids.
Ulipristal acetate-d6 is deuterium labeled Ulipristal acetate. Ulipristal acetate (CDB-2914) is an orally active, selective progesterone receptor modulator (SPRM). Ulipristal acetate stimulates the autophagic response selectively in leiomyoma cells. Ulipristal acetate has the potential for benign gynecological conditions treatment, such as uterine myoma.
分子式
C30H31D6NO4
分子量
481.65548
CAS号
1621894-64-1
中文名称
醋酸乌利司他-d6
运输条件
Room temperature in continental US; may vary elsewhere.